EAU 2017: Debate - Do we need to follow-up in low grade bladder tumor after 12 months?-Yes (EAU Guidelines)

London, England (UroToday.com) In this session, a debate ensued between two guidelines for the surveillance of low risk bladder tumors. Specifically, what is the best follow-up protocol for low risk tumors that do not recur? Is it 1 year as the NICE guidelines would suggest or 5 years as the EAU guidelines would suggest? Professor Burger was tasked with defending the EAU guideline recommendations of 5 years of total follow-up.

He began by demonstrating that most patients rate cystoscopy as a relatively painless experience. Thus, there is not a moral imperative to cease surveillance at 1 year. He then argued that a 1 year follow-up strategy will miss many recurrences. In fact, approximately 20-30% of recurrences occur between 1 and 5 years. In contrast, only 8% of patient who have not had a previous recurrence will develop one after 5 years. Thus, the logical time frame to stop surveillance remains after 5 years, but not after only 1 year.

Interestingly, Professor Burger then argued that ignoring surveillance after 1 year increases the probability of future symptomatic presentations. In a non-muscle invasive bladder cancer active surveillance (AS) cohort, approximately one-third of patients discontinued AS due to bothersome hematuria. Thus, there is a very real risk of symptomatic re-presentation if surveillance is discontinued after 1 year.

Guidelines set boundaries and do not set a rigid, prescribed treatment course. The EAU guidelines recommend that patients with low risk tumors should undergo cystoscopy at 3 months. If follow-up remains negative, subsequent cystoscopy is advised 9 months later and then annually for 5 years.

Speaker: M. Burger, Regensburg, DE

Written by: Benjamin T. Ristau, MD, SUO Fellow, Fox Chase Cancer Center, Philadelphia, PA.

at the #EAU17 -March 24-28, 2017- London, England

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.